 Jonathan Wagner
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2022 | 23 | 3.310 |
Why?
| | Hypercholesterolemia | 4 | 2024 | 12 | 2.860 |
Why?
| | Pravastatin | 3 | 2020 | 7 | 1.890 |
Why?
| | Genetic Variation | 5 | 2024 | 175 | 1.740 |
Why?
| | Child | 22 | 2024 | 3393 | 1.170 |
Why?
| | Humans | 28 | 2024 | 6915 | 1.120 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2024 | 6 | 0.950 |
Why?
| | Simvastatin | 2 | 2019 | 10 | 0.770 |
Why?
| | Adolescent | 11 | 2024 | 2235 | 0.720 |
Why?
| | Rosuvastatin Calcium | 1 | 2020 | 5 | 0.700 |
Why?
| | Male | 13 | 2023 | 3383 | 0.700 |
Why?
| | Pharmacogenetics | 4 | 2022 | 176 | 0.680 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2019 | 1 | 0.660 |
Why?
| | Cardiac Surgical Procedures | 2 | 2016 | 29 | 0.640 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2024 | 95 | 0.640 |
Why?
| | CHARGE Syndrome | 1 | 2017 | 1 | 0.570 |
Why?
| | Aortic Coarctation | 1 | 2017 | 5 | 0.570 |
Why?
| | Abnormalities, Multiple | 1 | 2017 | 36 | 0.550 |
Why?
| | Young Adult | 5 | 2024 | 657 | 0.540 |
Why?
| | Myxoma | 1 | 2016 | 1 | 0.540 |
Why?
| | Heart Neoplasms | 1 | 2016 | 2 | 0.540 |
Why?
| | Lactones | 1 | 2016 | 3 | 0.530 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2016 | 40 | 0.520 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 20 | 0.520 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 2 | 2013 | 3 | 0.510 |
Why?
| | Warfarin | 1 | 2015 | 12 | 0.500 |
Why?
| | Oseltamivir | 1 | 2015 | 6 | 0.500 |
Why?
| | Anticoagulants | 1 | 2015 | 18 | 0.500 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2015 | 19 | 0.490 |
Why?
| | Antiviral Agents | 1 | 2015 | 32 | 0.490 |
Why?
| | Oxygen Consumption | 3 | 2023 | 18 | 0.480 |
Why?
| | Female | 8 | 2023 | 3563 | 0.470 |
Why?
| | Sulfonamides | 3 | 2023 | 9 | 0.450 |
Why?
| | Pharmacokinetics | 1 | 2013 | 14 | 0.430 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 37 | 0.430 |
Why?
| | Pediatrics | 3 | 2024 | 185 | 0.420 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 7 | 0.420 |
Why?
| | Dyslipidemias | 1 | 2012 | 15 | 0.410 |
Why?
| | Angina Pectoris | 1 | 2012 | 1 | 0.410 |
Why?
| | Troponin | 1 | 2012 | 1 | 0.410 |
Why?
| | Genotype | 3 | 2024 | 410 | 0.380 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2021 | 20 | 0.370 |
Why?
| | Adult | 5 | 2024 | 1187 | 0.360 |
Why?
| | Exercise Test | 3 | 2023 | 17 | 0.300 |
Why?
| | Pediatric Obesity | 2 | 2021 | 139 | 0.290 |
Why?
| | Child Development | 2 | 2019 | 43 | 0.270 |
Why?
| | Fontan Procedure | 2 | 2023 | 19 | 0.260 |
Why?
| | Echocardiography | 3 | 2016 | 81 | 0.250 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2016 | 6 | 0.240 |
Why?
| | Pharmacology, Clinical | 1 | 2024 | 4 | 0.230 |
Why?
| | Heterozygote | 1 | 2024 | 26 | 0.230 |
Why?
| | Pyrimidines | 2 | 2023 | 7 | 0.230 |
Why?
| | Age Factors | 3 | 2021 | 211 | 0.230 |
Why?
| | Hyperlipidemias | 2 | 2019 | 6 | 0.190 |
Why?
| | Life Style | 1 | 2021 | 23 | 0.190 |
Why?
| | End Stage Liver Disease | 1 | 2021 | 3 | 0.190 |
Why?
| | Syncope | 1 | 2021 | 1 | 0.190 |
Why?
| | Weight Loss | 1 | 2021 | 39 | 0.180 |
Why?
| | Stereoisomerism | 1 | 2020 | 9 | 0.180 |
Why?
| | Inhibitory Concentration 50 | 1 | 2020 | 7 | 0.180 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2020 | 19 | 0.180 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2020 | 19 | 0.180 |
Why?
| | Heart Ventricles | 2 | 2023 | 49 | 0.180 |
Why?
| | HEK293 Cells | 1 | 2020 | 32 | 0.180 |
Why?
| | Patient Selection | 1 | 2021 | 39 | 0.180 |
Why?
| | Obesity | 1 | 2021 | 117 | 0.170 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2019 | 2 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 77 | 0.170 |
Why?
| | Heart Diseases | 1 | 2019 | 19 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2019 | 16 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2019 | 21 | 0.170 |
Why?
| | Thrombosis | 2 | 2019 | 14 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2019 | 8 | 0.160 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 5 | 0.160 |
Why?
| | Models, Biological | 1 | 2019 | 50 | 0.160 |
Why?
| | Genetic Association Studies | 1 | 2019 | 53 | 0.160 |
Why?
| | Treatment Outcome | 2 | 2019 | 624 | 0.160 |
Why?
| | Precision Medicine | 1 | 2019 | 49 | 0.150 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 348 | 0.150 |
Why?
| | Heart Defects, Congenital | 2 | 2021 | 80 | 0.150 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 91 | 0.150 |
Why?
| | Aortography | 1 | 2017 | 2 | 0.140 |
Why?
| | Disease Progression | 2 | 2021 | 111 | 0.140 |
Why?
| | Research Design | 2 | 2019 | 63 | 0.140 |
Why?
| | Infant, Newborn | 2 | 2017 | 825 | 0.140 |
Why?
| | Isomerism | 1 | 2016 | 2 | 0.130 |
Why?
| | Linear Models | 1 | 2016 | 56 | 0.130 |
Why?
| | Electrocardiography | 2 | 2013 | 14 | 0.130 |
Why?
| | International Normalized Ratio | 1 | 2015 | 4 | 0.130 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 149 | 0.130 |
Why?
| | Drug Interactions | 1 | 2015 | 32 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2016 | 201 | 0.120 |
Why?
| | Genetic Testing | 2 | 2013 | 87 | 0.120 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 2014 | 3 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2014 | 2 | 0.120 |
Why?
| | Embolization, Therapeutic | 1 | 2014 | 12 | 0.110 |
Why?
| | Influenza, Human | 1 | 2015 | 73 | 0.110 |
Why?
| | Biological Availability | 1 | 2013 | 8 | 0.110 |
Why?
| | Half-Life | 1 | 2013 | 12 | 0.110 |
Why?
| | Absorption | 1 | 2013 | 7 | 0.110 |
Why?
| | Tissue Distribution | 1 | 2013 | 11 | 0.110 |
Why?
| | Long QT Syndrome | 1 | 2013 | 3 | 0.110 |
Why?
| | Myocardium | 1 | 2012 | 12 | 0.100 |
Why?
| | Biopsy | 1 | 2012 | 61 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2023 | 45 | 0.100 |
Why?
| | Heart Rate | 2 | 2023 | 24 | 0.100 |
Why?
| | Biomarkers | 1 | 2012 | 133 | 0.100 |
Why?
| | Exercise | 2 | 2023 | 138 | 0.090 |
Why?
| | Biomedical Research | 1 | 2024 | 27 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2023 | 8 | 0.060 |
Why?
| | Blood Pressure | 1 | 2023 | 67 | 0.050 |
Why?
| | Haplotypes | 1 | 2022 | 91 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 339 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2022 | 96 | 0.050 |
Why?
| | Alleles | 1 | 2022 | 215 | 0.050 |
Why?
| | Unconsciousness | 1 | 2021 | 1 | 0.050 |
Why?
| | Syncope, Vasovagal | 1 | 2021 | 1 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2021 | 3 | 0.050 |
Why?
| | Cardiomyopathies | 1 | 2021 | 6 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 8 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 45 | 0.050 |
Why?
| | Seizures | 1 | 2021 | 25 | 0.050 |
Why?
| | Prognosis | 1 | 2021 | 212 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 1 | 0.040 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2019 | 6 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 35 | 0.040 |
Why?
| | Risk Factors | 1 | 2021 | 485 | 0.040 |
Why?
| | Comorbidity | 1 | 2019 | 56 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 10 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 46 | 0.040 |
Why?
| | Child, Preschool | 1 | 2021 | 1600 | 0.030 |
Why?
| | Cognition | 1 | 2014 | 32 | 0.030 |
Why?
| | Catheter Ablation | 1 | 2013 | 1 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2014 | 302 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2013 | 20 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 122 | 0.020 |
Why?
| | Mutation | 1 | 2013 | 213 | 0.020 |
Why?
| | Infant | 1 | 2014 | 1464 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|